Catalyst Event
Pfizer Inc (PFE) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/28/2026, 12:00:00 AM
Pfizer announced on April 28, 2026, that it reached settlement agreements with three generic drug manufacturers, extending U.S. patent protection for its blockbuster heart disease drug VYNDAMAX until June 1, 2031. High importance is estimated due to the long-term revenue protection.
Korean Translation
화이자는 2026년 4월 28일, 3개의 제네릭 의약품 제조업체와 합의에 도달하여 블록버스터 심장병 치료제 빈다맥스(VYNDAMAX)의 미국 내 특허 보호를 2031년 6월 1일까지 연장한다고 발표함. 장기적인 매출 보호 효과를 고려하여 중요도를 '높음'으로 예상함.
Related Recent Events
Bristol-Myers Squibb Co (BMY) · Other
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026, for its decision on iberdomide for relapsed or refractory multiple myeloma, scheduled. Low impact estimated as the target date is a procedural milestone.
8/17/2026, 12:00:00 AM
Blackstone Inc (BX) · Earnings Release
Blackstone is scheduled to release its Q2 2026 earnings results, with analysts forecasting earnings of approximately $1.34-$1.36 per share, scheduled.
7/23/2026, 12:00:00 AM
Union Pacific Corp (UNP) · Earnings Release
Q2 2026 earnings release is scheduled. Low impact estimated as the date announcement is a routine event; scheduled.
7/23/2026, 12:00:00 AM
Goldman Sachs Group Inc (The) (GS) · Earnings Release
Goldman Sachs' Q2 2026 earnings release is scheduled.
7/14/2026, 12:00:00 AM
NIKE Inc (NKE) · Earnings Release
Q4 Fiscal Year 2026 earnings release is scheduled for June 25, 2026. Low importance as the announcement of the date typically has a minimal market impact.
6/25/2026, 12:00:00 AM
Vistra Corp (VST) · Other
Quarterly dividend of $0.2290 per share with an ex-dividend date of June 22, 2026; low importance estimated as dividends usually cause minor price adjustments, scheduled.
6/22/2026, 12:00:00 AM